相似文献
1
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
J Natl Compr Canc Netw. 2017 May;15(5):563-573. doi: 10.6004/jnccn.2017.0059.
2
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310. doi: 10.6004/jnccn.2019.0019.
3
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.
J Natl Compr Canc Netw. 2022 Mar;20(3):224-234. doi: 10.6004/jnccn.2022.0016.
4
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002.
5
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20. doi: 10.6004/jnccn.2017.0003.
6
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
J Natl Compr Canc Netw. 2023 Jul;21(7):694-704. doi: 10.6004/jnccn.2023.0035.
7
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
J Natl Compr Canc Netw. 2013 May 1;11(5):519-28. doi: 10.6004/jnccn.2013.0069.
8
Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region.
J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S36-40. doi: 10.6004/jnccn.2010.0123.
9
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.
J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. doi: 10.6004/jnccn.2018.0013.
10
Rectal Cancer, Version 2.2015.
J Natl Compr Canc Netw. 2015 Jun;13(6):719-28; quiz 728. doi: 10.6004/jnccn.2015.0087.
引用本文的文献
1
Early prediction of proton therapy dose distributions and DVHs for hepatocellular carcinoma using contour-based CNN models from diagnostic CT and MRI.
Radiat Oncol. 2025 Aug 4;20(1):122. doi: 10.1186/s13014-025-02708-6.
2
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric.
ILIVER. 2024 Feb 6;3(1):100077. doi: 10.1016/j.iliver.2024.100077. eCollection 2024 Mar.
3
Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study.
Medicine (Baltimore). 2025 Jun 13;104(24):e42834. doi: 10.1097/MD.0000000000042834.
4
Hepatocellular carcinoma cell-derived small extracellular vesicle-associated CD147 serves as a diagnostic marker and promotes endothelial cell angiogenesis via the PI3K/Akt pathway.
Extracell Vesicles Circ Nucl Acids. 2023 Oct 12;4(4):532-547. doi: 10.20517/evcna.2023.30. eCollection 2023.
5
Application of immunofluorescence-based detection of AFP-L3 in the diagnosis of hepatocellular carcinoma.
Medicine (Baltimore). 2025 Apr 18;104(16):e42194. doi: 10.1097/MD.0000000000042194.
6
Advances in radiation therapy for HCC: Integration with liver-directed treatments.
Hepatol Commun. 2025 Mar 21;9(4). doi: 10.1097/HC9.0000000000000653. eCollection 2025 Apr 1.
7
Factors associated with uptake of human papilloma virus vaccine among adolescent girls: A cross sectional survey on insights into HPV Infection Prevention in Kabarole District, Western Uganda.
PLoS One. 2025 Mar 10;20(3):e0306960. doi: 10.1371/journal.pone.0306960. eCollection 2025.
8
Management of advanced gallbladder adenocarcinoma: A case report and review of treatment strategies.
Int J Surg Case Rep. 2025 Feb;127:110965. doi: 10.1016/j.ijscr.2025.110965. Epub 2025 Jan 27.
9
Gut Microbiota as Mediator and Moderator Between Hepatitis B Virus and Hepatocellular Carcinoma: A Prospective Study.
Cancer Med. 2024 Dec;13(24):e70454. doi: 10.1002/cam4.70454.
10
Machine learning based on alcohol drinking-gut microbiota-liver axis in predicting the occurrence of early-stage hepatocellular carcinoma.
BMC Cancer. 2024 Nov 29;24(1):1468. doi: 10.1186/s12885-024-13161-1.
本文引用的文献
1
Local ablative treatments for hepatocellular carcinoma: An updated review.
World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):477-489. doi: 10.4292/wjgpt.v7.i4.477.
2
Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis.
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):477-482. doi: 10.1016/j.ijrobp.2016.02.027. Epub 2016 Feb 13.
3
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.
Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9.
4
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
5
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
J Clin Oncol. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1.
6
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
7
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14.
8
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
J Clin Oncol. 2016 Feb 10;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. Epub 2015 Nov 30.
9
Aggressive Intrasegmental Recurrence of Periportal Hepatocellular Carcinoma after Radiofrequency Ablation: Role of Ablative Technique and Heat-Sink Effect?
Radiology. 2015 Sep;276(3):932-3. doi: 10.1148/radiol.2015150661.
10
Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Radiother Oncol. 2015 Mar;114(3):289-95. doi: 10.1016/j.radonc.2014.11.033. Epub 2014 Dec 9.
Zotero 插件